Rahul Banerjee, Andrew J Cowan, Marivel Ortega, Constance Missimer, Paul A Carpenter, Masumi Ueda Oshima, Rachel B Salit, Phuong T Vo, Catherine J Lee, Rohtesh S Mehta, Nicole M Kuderer, Veena Shankaran, Stephanie J Lee, Christopher T Su
BACKGROUND: Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized. PATIENTS AND METHODS: We conducted a single-center cross-sectional survey of patients with MM who had undergone transplantation. FinTox+ was defined as a COST-FACIT score <23, TimeTox+ as MM-related interactions (including phone calls) ≥1x weekly or ≥1x monthly in-person among far-residing patients, QOL using PROMIS Global Health, and functional status using patient-reported Karnofsky performance status (KPS)...
February 23, 2024: Clinical Lymphoma, Myeloma & Leukemia